Eckert & Ziegler Strahlen und Medizintechnik (EUZ) AI Stock Analysis

• Market Cap: €1.35B
• Dividend Yield: 0.08%
• Average Volume (3M): 32.42K
• Price to Earnings (P/E): 39.3
• Beta (1Y): 1.24
• Revenue Growth: 15.89%
• EPS Growth: 14.62%
• Country: DE
• Employees: 1,085
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Devices
• EPS (TTM): 0.47
• Shares Outstanding: 21,171,932
• 10 Day Avg. Volume: 27,506
• 30 Day Avg. Volume: 32,418
• PEG Ratio: -3.43
• Price to Book (P/B): 4.77
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 27.05
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €67.55
• Price Target Upside: 3.84% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 78 Outperform
• Price Target: €75.00 ▲(15.30%Upside)

The overall score is driven by a strong financial performance and positive technical indicators. The company's financial health is solid, with impressive revenue growth and cash flow generation, which supports future growth. Technical analysis shows strong bullish momentum, although the stock is approaching overbought levels. The valuation appears stretched, with a high P/E ratio, but this is partially offset by the dividend yield.

Eckert & Ziegler Strahlen und Medizintechnik Business Overview & Revenue Model

Company Description

Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide. It operates in two segments, Medical and Isotope Products. The Medical segment offers small radioactive implants for the treatment of prostate cancer seeds; and eye application based on ruthenium-106 or iodine-125 for treating uveal melanoma. This segment also provides radiopharmaceuticals, laboratory equipment, hot cells, and services for radiopharmaceuticals, as well as eye applicators and prostate implants. The Isotope Products segment manufactures and sells radiation sources for imaging, measurement technology, material analysis, quality assurance, and environmental monitoring. This segment also offers calibration sources for medical imaging systems, and homeland security and radiometric level measurement products. The company was founded in 1992 and is headquartered in Berlin, Germany.

How the Company Makes Money

Eckert & Ziegler generates revenue through the sale of its radiopharmaceuticals for nuclear medicine, which are used in diagnostic imaging and cancer therapy. The company also earns income from its radiation therapy devices, which are utilized in hospitals and clinics for treating various cancers. Additionally, Eckert & Ziegler's industrial segment provides radiation measurement and imaging solutions for a variety of industries. Significant partnerships with healthcare institutions and research organizations enhance its market reach, further contributing to its earnings.

Eckert & Ziegler Strahlen und Medizintechnik Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
277.73M	246.09M	222.26M	180.44M	176.14M	178.49M
	Gross Profit
133.54M	116.34M	106.78M	91.08M	86.53M	87.02M
	EBIT
63.59M	47.00M	42.44M	46.03M	35.24M	31.63M
	EBITDA
70.63M	59.67M	56.70M	56.68M	42.31M	42.93M
	Net Income Common Stockholders
29.34M	26.30M	29.28M	34.53M	21.29M	22.02M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
60.05M	68.00M	82.70M	95.02M	88.61M	78.92M
	Total Assets
253.23M	439.36M	416.84M	347.73M	292.00M	274.24M
	Total Debt
19.56M	56.30M	49.59M	26.97M	20.40M	19.89M
	Net Debt
-40.49M	-11.69M	-33.11M	-66.69M	-67.07M	-59.04M
	Total Liabilities
122.34M	215.27M	203.21M	155.20M	143.08M	134.79M
	Stockholders Equity
129.51M	222.18M	212.07M	187.39M	147.82M	138.19M
Cash Flow		Free Cash Flow
43.86M	21.12M	3.17M	5.00M	27.88M	33.17M
	Operating Cash Flow
62.76M	46.95M	34.30M	33.85M	36.79M	40.43M
	Investing Cash Flow
-22.35M	-42.74M	-41.04M	-23.59M	-13.35M	-5.65M
	Financing Cash Flow
-20.17M	-9.28M	-5.71M	-6.06M	-12.96M	-10.50M

Eckert & Ziegler Strahlen und Medizintechnik Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 65.05
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:EUZ, the sentiment is Positive. The current price of 65.05 is above the 20-day moving average (MA) of 62.94, above the 50-day MA of 57.95, and above the 200-day MA of 49.33, indicating a bullish trend. The MACD of 1.75 indicates Negative momentum. The RSI at 60.52 is Neutral, neither overbought nor oversold. The STOCH value of 84.29 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:EUZ.

Eckert & Ziegler Strahlen und Medizintechnik Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EUZ	78 Outperform	€1.35B	39.33	17.48%	0.08%	15.89%	14.62%
Sector *	54 Neutral	$5.31B	3.29	-45.39%	2.79%	16.77%	-0.07%
0N6Z		€1.40B	61.76	-4.72%	0.10%	―	―
0N70		€1.40B	44.66	-4.72%	0.26%	―	―
0MSD		€1.16B	33.13	5.26%	6.17%	―	―
0IRF		€1.25B	―	-20.51%	―	―	―
FYB	63 Neutral	€484.01M	5.89	-26.06%	―	-10.32%	-250.76%